Astrazeneca (AZNCF) Research & Development (2016 - 2025)
Historic Research & Development for Astrazeneca (AZNCF) over the last 16 years, with Q4 2025 value amounting to -$3.9 billion.
- Astrazeneca's Research & Development rose 1742.57% to -$3.9 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$14.2 billion, marking a year-over-year decrease of 477.8%. This contributed to the annual value of -$14.2 billion for FY2025, which is 477.8% down from last year.
- Per Astrazeneca's latest filing, its Research & Development stood at -$3.9 billion for Q4 2025, which was up 1742.57% from -$3.7 billion recorded in Q3 2025.
- Astrazeneca's 5-year Research & Development high stood at -$302.0 million for Q1 2021, and its period low was -$4.7 billion during Q4 2024.
- Moreover, its 5-year median value for Research & Development was -$2.7 billion (2023), whereas its average is -$2.8 billion.
- In the last 5 years, Astrazeneca's Research & Development soared by 7824.21% in 2021 and then plummeted by 60629.14% in 2022.
- Over the past 5 years, Astrazeneca's Research & Development (Quarter) stood at -$2.6 billion in 2021, then decreased by 1.59% to -$2.6 billion in 2022, then dropped by 17.07% to -$3.1 billion in 2023, then tumbled by 52.2% to -$4.7 billion in 2024, then grew by 17.43% to -$3.9 billion in 2025.
- Its last three reported values are -$3.9 billion in Q4 2025, -$3.7 billion for Q3 2025, and -$3.5 billion during Q2 2025.